Geode Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Geode Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-67,032	Closed	-$8.71K	–	4469
2025 Q3	$8.71K	Hold	67,032	–	–	﹤0.01%	4452
2025 Q2	$16.1K	Sell	67,032 -42,034	-39%	-$11.2K	﹤0.01%	4387
2025 Q1	$21.5K	Sell	109,066 -30,735	-22%	-$15.9K	﹤0.01%	4333
2024 Q4	$75.3K	Hold	139,801	–	–	﹤0.01%	4167
2024 Q3	$133K	Buy	139,801 +21,892	+19%	+$24.8K	﹤0.01%	4030
2024 Q2	$115K	Hold	117,909	–	–	﹤0.01%	4096
2024 Q1	$186K	Hold	117,909	–	–	﹤0.01%	3963
2023 Q4	$93.5K	Hold	117,909	–	–	﹤0.01%	4206
2023 Q3	$92K	Hold	117,909	–	–	﹤0.01%	4274
2023 Q2	$109K	Buy	117,909 +11,999	+11%	+$14.3K	﹤0.01%	4304
2023 Q1	$115K	Hold	105,910	–	–	﹤0.01%	4293
2022 Q4	$154K	Buy	105,910 +33,141	+46%	+$53.7K	﹤0.01%	4220
2022 Q3	$78K	Hold	72,769	–	–	﹤0.01%	4655
2022 Q2	$123K	Hold	72,769	–	–	﹤0.01%	4501
2022 Q1	$149K	Hold	72,769	–	–	﹤0.01%	4510
2021 Q4	$272K	Hold	72,769	–	–	﹤0.01%	4342
2021 Q3	$376K	Hold	72,769	–	–	﹤0.01%	4163
2021 Q2	$309K	Hold	72,769	–	–	﹤0.01%	4150
2021 Q1	$386K	Buy	72,769 +23,581	+48%	+$135K	﹤0.01%	3893
2020 Q4	$265K	Sell	49,188 -61,467	-56%	-$334K	﹤0.01%	3802
2020 Q3	$883K	Buy	110,655 +49,703	+82%	+$435K	﹤0.01%	3258
2020 Q2	$610K	Buy	60,952 +9,563	+19%	+$60.1K	﹤0.01%	3301
2020 Q1	$139K	Sell	51,389 -46,618	-48%	-$155K	﹤0.01%	3656
2019 Q4	$117K	Buy	98,007 +34,007	+53%	+$36.3K	﹤0.01%	3947
2019 Q3	$96K	Hold	64,000	–	–	﹤0.01%	3952
2019 Q2	$257K	Hold	64,000	–	–	﹤0.01%	3713
2019 Q1	$275K	Buy	64,000 +24,752	+63%	+$115K	﹤0.01%	3642
2018 Q4	$225K	Sell	39,248 -407	-1%	-$3K	﹤0.01%	3640
2018 Q3	$537K	Sell	39,655 -1,482	-4%	-$15.5K	﹤0.01%	3438
2018 Q2	$487K	Sell	41,137 -2,074	-5%	-$25.9K	﹤0.01%	3451
2018 Q1	$485K	Buy	43,211 +14,544	+51%	+$127K	﹤0.01%	3406
2017 Q4	$191K	Buy	28,667 +62	+0.2%	+$479	﹤0.01%	3690
2017 Q3	$234K	Hold	28,605	–	–	﹤0.01%	3620
2017 Q2	$128K	Buy	28,605 +11,764	+70%	+$61.5K	﹤0.01%	3787
2017 Q1	$92K	Buy	16,841 +420	+3%	+$1.84K	﹤0.01%	3841
2016 Q4	$66K	Buy	16,421 +280	+2%	+$1.34K	﹤0.01%	3870
2016 Q3	$113K	Buy	16,141 +5,868	+57%	+$44.8K	﹤0.01%	3778
2016 Q2	$83K	Buy	+10,273	New	+$96.7K	﹤0.01%	3839

Other funds holding ADAP

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management's ADAP Position: Q4 2025 in Review

Geode Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 67,032 shares — an estimated $8.71K sold.

Geode Capital Management first reported a position in ADAP in Q2 2016 and held it in 38 quarters. The position peaked at $883K in Q3 2020. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

Geode Capital Management reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
Geode Capital Management sold 67,032 Adaptimmune Therapeutics shares in Q4 2025, an estimated $8.71K.
Geode Capital Management first reported a position in Adaptimmune Therapeutics in Q2 2016 and held it in 38 quarters.
Geode Capital Management's Adaptimmune Therapeutics position peaked at $883K in Q3 2020.
10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Geode Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.